FDA approves Teva Pharmaceuticals’ CU method

By The Science Advisory Board staff writers

July 7, 2022 -- The U.S. Food and Drug Administration (FDA) approved a content uniformity (CU) method from Teva Pharmaceuticals that uses the Agilent TRS100 Raman quantitative pharmaceutical analysis system.

As an Agilent Raman spectroscopy customer, Teva Pharmaceuticals developed a method of CU that determines how much active pharmaceutical ingredient (API) is inside a tablet or capsule and whether the API is uniform across a batch. The method is a fast, whole-sample analysis that negates the sample preparation stages and allows the test to be completed in a matter of minutes, Teva Pharmaceuticals said.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.